Alcohol Abstinence: Campral Now FDA-Approved

December 31, 2006

Acamprosate calcium (Campral)from Lipha Pharmaceuticals, Inc,has been approved by the FDAfor the treatment of alcohol-dependentpersons who wish to remain alcohol-free after they have stoppeddrinking. Although its mechanismof action is not fully understood,this drug was shown to be more effectivethan placebo in maintainingabstinence. Acamprosate is nonaddictiveand has been shown to bewell tolerated in clinical trials. Themost common adverse effects areheadache, diarrhea, flatulence, andnausea.

New Drug to MaintainAlcohol AbstinenceAcamprosate calcium (Campral)from Lipha Pharmaceuticals, Inc,has been approved by the FDAfor the treatment of alcohol-dependentpersons who wish to remain alcohol-free after they have stoppeddrinking. Although its mechanismof action is not fully understood,this drug was shown to be more effectivethan placebo in maintainingabstinence. Acamprosate is nonaddictiveand has been shown to bewell tolerated in clinical trials. Themost common adverse effects areheadache, diarrhea, flatulence, andnausea.